Currently, methods to treat ROP produce only modest benefits; anti‐VEGFA and laser ablation therapy can temporarily control neovascularization, but the long‐term efficacy is limited, and repeated anti‐VEGF injection may cause VEGFA resistance and other side effects in children.44, 45. The gene discussed is VEGFA; the disease is retinopathy of prematurity.